What is the price target for BLTE stock?
14 analysts have analysed BLTE and the average price target is 215.73 USD. This implies a price increase of 35.91% is expected in the next year compared to the current price of 158.73.
BELITE BIO INC - ADR (BLTE) Forecast, Price Target & Analyst Ratings
NASDAQ:BLTE • US07782B1044
Current stock price
158.73 USD
-4.33 (-2.66%)
At close:
158.73 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BELITE BIO INC - ADR (BLTE).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 11, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.65
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$215.73
Upside
+ 35.91%
From current price of $158.73 to mean target of $215.73, Based on 14 analyst forecasts
Low
$186.85
Median
$204.51
High
$279.30
Price Target Revisions
1 Month
11.24%
3 Months
14.15%
Price Target Summary
14 Wall Street analysts provided a forecast for the next 12 months for BLTE. The average price target is 215.73 USD. This implies a price increase of 35.91% is expected in the next year compared to the current price of 158.73.
The average price target has been revised upward by 14.15% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.29%
BLTE was analyzed by 14 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about BLTE.
In the previous month the buy percentage consensus was at a similar level.
BLTE was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-04-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-03-03 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2026-03-03 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2026-03-03 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-01-26 | B of A Securities | Initiate | Buy |
| 2026-01-06 | Morgan Stanley | Initiate | Overweight |
| 2025-12-02 | Mizuho | Upgrade | Neutral -> Outperform |
| 2025-12-01 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-20 | Mizuho | Initiate | Neutral |
| 2025-10-31 | Benchmark | Maintains | Buy -> Buy |
| 2025-09-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-07-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-15 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-26 | Benchmark | Reiterate | Buy -> Buy |
| 2025-03-18 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-03-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-21 | Benchmark | Maintains | Buy -> Buy |
| 2024-11-15 | Maxim Group | Maintains | Buy -> Buy |
| 2024-11-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-09-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-13 | Benchmark | Reiterate | Buy -> Buy |
| 2024-08-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 11, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.65
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- -44.42%
- Number of Analysts
- 10
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
-2.35%
Next Earnings Summary
BLTE is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -0.65 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A 492.11% | N/A 218.26% | N/A 132.38% | N/A 43.08% | N/A 40.06% | N/A 25.97% | N/A 10.96% | |||||||
| EBITDA YoY % growth | -5.72M | -9.77M -70.80% | -12.76M -30.60% | -31.529M -147.09% | -39.828M -26.32% | -84.024M -110.97% | N/A 50.92% | N/A 452.23% | N/A 288.69% | N/A 125.48% | N/A 25.61% | N/A 22.89% | N/A 34.86% | N/A 2.75% | |
| EBIT YoY % growth | -5.74M | -9.8M -70.73% | -12.82M -30.82% | -31.668M -147.02% | -39.996M -26.30% | -84.208M -110.54% | N/A -7.55% | N/A 21.49% | N/A 304.06% | N/A 376.85% | N/A 48.15% | N/A 34.73% | N/A 29.62% | N/A 10.84% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -1.24 -85.60% | -1.18 4.84% | -2.30 -94.92% | N/A 8.39% | N/A -12.96% | N/A 267.86% | N/A 365.36% | N/A 30.63% | N/A 43.41% | N/A 30.36% | N/A 8.07% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.65 -44.42% | -0.68 -36.97% | -0.71 -8.95% | -0.08 87.93% | -0.42 35.65% | -0.13 80.64% | 0.09 112.96% | 0.37 534.47% |
| Revenue Q2Q % growth | 26.229M | 16.513M | 32.977M | 48.36M | 64.459M 145.75% | |||
| EBITDA Q2Q % growth | -28.897M | -29.764M | -30.957M | -35.221M -37.73% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -26.87M -73.17% | -27.98M -59.01% | -28.865M -196.35% | -5.023M 90.98% | -16.354M 39.14% | -5.256M 81.21% | 3.783M 113.11% | 14.608M 390.84% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
55.18%
EPS Next 5 Year
65.88%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
108.85%
EBIT Next 5 Year
85.79%
BELITE BIO INC - ADR / BLTE Forecast FAQ
Can you provide the upcoming earnings date for BELITE BIO INC - ADR?
BELITE BIO INC - ADR (BLTE) will report earnings on 2026-05-11.
Can you provide the consensus estimates for BELITE BIO INC - ADR next earnings?
The consensus EPS estimate for the next earnings of BELITE BIO INC - ADR (BLTE) is -0.65 USD and the consensus revenue estimate is 0 USD.
How many analysts have analysed BELITE BIO INC - ADR (BLTE)?
The number of analysts covering BELITE BIO INC - ADR (BLTE) is 14.